BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 1 of 48 Safety and T olerability O f Allogeneic M esenchymal Stromal Cells in 
Pediatric and Adult Inflammatory Bowel Disea se (STOMP)  
 
 
 
SPONSOR  
Catherine Bollard,  MD, MBChB  
 
 
PRINCIPAL INVESTIGATOR  
Laurie S. Conklin , MD  
  
CO-INVESTIGATORS  
Fahmida Hoq, MBBS, MS  
Sona Sehgal, MD  
Teena Sebastian, MD  
Patrick Hanley, PhD  
 
STATISTICIAN S: 
Yunfei Wang, PhD  
 
CENTER  
Childrenâ€™s National Medical Center  
Center for Cancer and Blood Disorders  
111 Michigan Avenue, NW  
Washington, DC 20010  
(202) 476- 5000  
    
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 2 of 48  
 Emergency Contact Information    
Role in Study  Name  Email and Telephone Number  
Sponsor  Catherine Bollard, M.D., 
FRACP, FRCPA  cbollard@cnmc.org/ 202 -476-4776  
Principal Investigator  Laurie S. Conklin , MD   
 LConklin@childrensnational.org/  
(202) 476 -3032  
Co-investigators  Patrick Hanley PhD  
 
 
Fahmida Hoq, MBBS, MS  
 
Sona Sehgal, MD  
 
Teena Sebastian, MD  PHanley@childrensnational.org/202 -
476-6368  
 
fhoq@childrensnational.org/202 -476-
3634 
ssehgal@childrensnational.org/202 -
476-3032  
tsebasti@ childrensnational .org/202 -
476-3032  
 
Institutional Review Board CNMC Institutional Review Board 801 Roeder Road  
Suite 801  
Silver Spring, Maryland, 20910/301-
565-8452  
Study Coordinator  Nana Ama Afari-Dwamena  nafaridwam@childrensnational.org  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 3 of 48 Name of Sponsor/Company:  
Catherine Bollard, M.D., FRACP, FRCPA  
 
Title of Study:  
 
Safety and Tolerability of Allogeneic Mesenchymal Stromal Cells in Pediatric and 
Adult Inflammatory Bowel Disease (STOMP  trial) 
Study Center(s):   Childrenâ€™s National Medical Center (CNMC)  
 
Principal Investigator:     Laurie S. Conklin, MD  
 
Co-investigators : Patrick Hanley PhD, Fahmida Hoq, MBBS, MS , Sona Sehgal, MD, 
Teena Sebastian, MD  
 
Objectives:  
 
Primary Objective:  
 
This is a pilot phase 1 study of Mesenchymal Stromal Cells (MSCs) for treatment of 
children and young adult patients  with refractory  Crohnâ€™s Disease (CD) or ulcerative 
colitis (UC). The primary aim is to evaluate safety and tolerability of the intervention.   
 
Secondary Objectives :  
 
1. Examine the  effects of 4  weekly  infusions of MSCs on  clinical indices , and endoscopic 
scores when available.   
 
2. Examine inflammat ory and immunologic effects of MSC infusions on peripheral and 
intestinal mucosal biomarkers including, but not limited to , serum C-reactive protein, fecal  
calprotectin, anti -HLA antibodies , and viral specific T- cell activity  before and after 
treatment.  
 
 
 
Study Design:    
This study is a pilot phase 1 study  of patients with moderately to severely active Crohn  
Disease  (CD) and ulcerative colitis (UC) (â‰¥ 18 years, Mayo score: â‰¥6 or CDAI: Ëƒ 220; <18 
years, Pediatric Crohnâ€™s Disease Activity Index (PCDAI ) :> 30) or Pediatric Ulcerative 
Colitis Activity Index (PUCAI ) : >34).  [1] [2]   A fixed dose will be studied:  1 x 10
6 cells/kg  
administered  intravenously (IV) weekly for 4  consecutive weeks , with the option of an 
additional 4 weeks of treatment , at the discretion of the principal investigator.  The primary 
outcomes are regimen- related toxicity, defined in section  5. Toxicity will be scored as a 
binary variable indicating occurrence or non- occurrence over a monitoring interval from 
the start of MSC therapy to 45 days after the last infusion. Based on  the planned 
administration schedule of 4 weeks , the total toxicity monitoring period will have duration 
28 +45 = 73 days . If additional weekly doses are administered, the safety assessment 
phase will be 45 days after the last dose given.  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 4 of 48 Three  young adult patient s (ages  17â‰¤22 years) will be enrolled , staggered by at least 7 
days,  and monitored for toxicity  over a period of 73  days .  Infusions are administered 
over the first 28 days, followed by a 45 day m onitoring period. If we observe no sever e 
(grade 3 or worse) adverse events in the young adult cohort, we will  wait a minimum of  
45 days after the last MSC administration before  beginning to enroll  3 more patients, 
ages 12â‰¤16 (pediatric cohort).  If we observe a  severe (grade 3 or worse) adverse event 
occurring at any time from the start of therapy to 45 days following the last MSC 
administration in the young adult cohort we will stop the study. If we observe no severe 
adverse events  attributable to MSCs  in the young adult cohort but a  severe (grade 3 or 
worse) adverse event occurring at any time from the start of therapy to 45 days following 
the last MSC administration in the pediatric cohort we will stop the study.   A maximum  of 
6 patients will be enrolled. Assuming an accrual rate of 3 -4 patients per year,  it is 
anticipated that it will require at least 18- 24 months to accrue all  6 patients.  
Eligibility  
This protocol allows for the treatment of both male and female pediatric  and young adult  
patients, between the ages of 12 â‰¤ 22 years , with a ctive moderate to severe CD  or UC,  
who have failed to respond to , or are intolerant of,  biologic therapy.  
 
Inclusion  criteria  
 
â€¢ For the young adult cohort, patients must be  ages 1 7 â‰¤22 years  
â€¢ For the pediatric cohort, patients must be ages 12  â‰¤16 years  
â€¢ Patients must have moderate -severely active  CD or UC  (defined in section 2.3), 
and documented active disease on flexible sigmoidoscopy , colonoscopy or MR 
enterography within the preceding 2 months.  
â€¢ Patients who have failed or are intolerant of biologic therapy.  Specifically, the 
patient will have recurrence or persistence of active disease despite current or past treatment with a biologic.  At the time of enrollment, study subjects may be 
currently receiving 5- aminosalicylates, corticosteroids (â‰¤ 20 mg daily or up to 0.5 
mg/kg/day if weight <40 kg), methotrexate, 6MP/azathioprine, or a biologic (either as monotherapy or in combination). During the treatment  phase, if the treating 
physician thinks that a medication dose should be lowered to avoid side effects, 
this should be recorded.  
â€¢ Patient or parent/guardian capable of providing informed consent.  
 
Exclusion criteria  
â€¢ Patients  < 12 years of age or > 22 years of age  
â€¢ Pregnant or breastfeeding. Serum pregnancy test must be negative at screening 
for female subjects of childbearing potential. Urine pregnancy test must remain 
negative at each of 4  infusion visits.  
â€¢ Patients with toxic mega -colon or intestinal perforation 
â€¢ Evidence of autoimmune chronic active hepatitis or sclerosing cholangitis.  
â€¢ Patients with fever > 39Â° C or clinically significant active infection within 1 week 
(i.e. chronic infections including Hepatitis B/C or HIV or acute infections, including 
urinary tract infection and respiratory tract infection)  
â€¢ Received an agent not appr oved by the FDA for marketed use in any indication or 
any small molecule inhibitors (i.e. naltrexone) within 60 days of enrollment.   
â€¢ Subjects who are taking greater than 20 mg (or if body weight <40 kg, 0.5 mg/kg) 
of prednisone daily.  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 5 of 48  
 
      â€¢ Clinically signific ant a bnormal biochemical and hematological parameters, 
including:  
o Neutrophil count < 1000 cells/mm3 
o Hemoglobin < 8 g/dl  
o Platelet count â‰¤ 130 cells/mm3 
o Creatinine â‰¥ 1.2 x the upper limit of normal  
o Alanine aminotransferase (ALT) and/or aspartate aminotransf erase 
(AST) â‰¥ 2x the upper limit of normal  
o Conjugated bilirubin greater than 1.2 . mg/dL  
â€¢ Has active infection with enteric pathogens as evidenced by positive 
microbiological culture of stool or C.difficile toxin PCR.  
â€¢ Had bowel surgery other than perianal procedures (fistulotomy, seton placement, 
abscess drainage) within  3 months of enrollment.  
â€¢ Has uveitis  
â€¢ Has known pulmonary disease, excluding mild intermittent asthma  
 
Primary Endpoint s 
 
â€¢ Safety and tolerability of the intravenous administration of human allogeneic bone 
marrow -derived MSCs  to children and young adults with IBD, measured by the 
frequency of  any SAEs, AEs and/or early treatment discontinuations.  
 
Secondary Endpoints  
â€¢ Magnitude of decrease in clinical index (for young adults we will use the CDAI and 
Mayo, and for children the PCDAI and PUCAI ) relative to baseline, reporting the 
average decline and 95% confidence limit .  
â€¢ Changes in biomarkers of inflammation and immunogenicity  (i.e. C -reactive protein, 
fecal calprotectin , anti -HLA antibodies , viral -specific T cell activity )  
â€¢ Where available, m agnitude of endoscopic improvement , as assessed by change in 
endoscopic scores (Simple Endoscopic Score Crohnâ€™s Disease [SES -CD] for CD o r 
Endoscopic Sub Score within the Mayo Score for UC)  relative to baseline, reporting 
the average decline and 95% confidence intervals  [3, 4]. 
 
Exploratory Endpoints  
Blood, urine, saliva, and stool  will be collected for evaluation of biomarkers  
 Accrual Period:  Estimated accrual of 3 -4 patients per year for 18 -24 months  
 Study Duration:       Approximately 48 months , including follow up 
 
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 6 of 48  
TABLE OF CONTENTS  
1 BACKGROUND AND RATIONALE  ............................................................................... 8 
1.1 Inflammatory Bowel Disease:  ...................................................................................... 8 
1.3 Description of the Study Agent/Intervention  .............................................................. 9 
1.4 Scientific Rationale and Clinical Justification  .......................................................... 11 
1.4.1  Rationale for the study of BMSCs in Pediatric IBD  ........................... 11 
1.4.2  PLAN OF STUDY:  ................................................................................. 13 
1.4.3  Rationale for the Dosage and Treatment Period  ............................... 14 
2 STUDY OBJECTIVES AND DESIGN  .......................................................................... 15 
2.1 Study Objectives:  ......................................................................................................... 15 
2.1.1  Primary Objective:  ................................................................................ 15 
2.1.2  Secondary objectives:  ......................................................................... 15 
2.2 Study Design  ................................................................................................................ 15 
2.2.1  Primar y Endpoint  ................................................................................. 17 
2.2.2  Secondary Endpoints  .......................................................................... 17 
2.2.3  Exploratory Endpoint  ........................................................................... 17 
2.3 Study Population  .......................................................................................................... 17 
2.4 Recr uitment Plan  ......................................................................................................... 18 
2.5 Informed Consent  ........................................................................................................ 18 
2.6 Eligibility criteria  ........................................................................................................... 19 
2.6.1 Subject Inclusion Criteria  .................................................................... 19 
2.6.2  Subject Exclusion Criteria  ................................................................... 19 
3 Study Agent  ...................................................................................................................... 20 
3.1 Preparation Administration, and Dosage  ................................................................. 20 
3.2 Assessment of Subject Compliance  ......................................................................... 21 
3.3 Concomitant Medications and Procedures  .............................................................. 22 
3.4 Prohibited Medications and Procedures  .................................................................. 22 
3.5 Study Schedule  ............................................................................................................ 22 
3.6 Table 1: Protocol of Events  ........................................................................................ 22 
3.7 Baseline assessment/screening  ................................................................................ 25 
3.8 Treatment Phase (Day 0, 7, 14, 21)  ......................................................................... 25 
Safety Monitoring Phase (Day 28, 45, 56, 73) +/ - 3 days  ................................................ 25 
3.9 Study Procedures  ........................................................................................................ 25 
3.9.1  Phlebotomy  ........................................................................................... 25 
4 Potential Risks and Benefits  .......................................................................................... 26 
4.1 Allogeneic BMSC Infusion  .......................................................................................... 26 
4.2 Phlebotomy  ................................................................................................................... 26 
4.3 Possibility of Direct Benefit  ........................................................................................ 26 
5 DRUG TOXICITY AND/OR ADVERSE REACTIONS (AEs)  .................................... 26 
5.1 ADVERSE EVENT  ...................................................................................................... 27 
5.2 SERIOU S ADVERSE EVENT  ................................................................................... 27 
5.3 UNEXPECTED ADVERSE EVENT  .......................................................................... 28 
5.4 OTHER ADVERSE EVENT  ....................................................................................... 28 
5.5 RELATIONSHIP TO TREATMENT  .......................................................................... 28 
5.7 Severity Assessment  .................................................................................................. 30 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 7 of 48 6 Off TREATMENT AND OFF STUDY CRITERIA ........................................................ 31 
7 Statistical Considerations  ............................................................................................... 32 
7.1 Statistical Analysis Plan  .............................................................................................. 32 
8 RECORDS TO BE KEPT  ............................................................................................... 32 
8.1 Data Handling and Record Keeping  ......................................................................... 33 
8.1.1  Data Management Responsibilities  .................................................... 33 
8.1.2  Data Capture Methods  ......................................................................... 33 
8.1.3 Types of Data  ........................................................................................ 33 
8.1.4  Source Documents and Access to Source Data/Documents  ........... 33 
8.1.5  Record Retention  ................................................................................. 34 
9 REPORTING REQUIREMENTS  .................................................................................. 34 
9.1 Adverse Event Reporting  ........................................................................................... 34 
9.2 Reporting to the IRB  .................................................................................................... 35 
9.3 Pregnancy Reporting  .................................................................................................. 35 
9.4 IND Annual Report to the FDA  .................................................................................. 35 
9.5 Final Report  .................................................................................................................. 36 
9.6 Reporting to the FDA  .................................................................................................. 36 
10 CLINICAL TRIAL OVERSIGHT AND MONITORING  ................................................ 36 
10.1  Safety monitoring  ..................................................................................................... 36 
10.2  Data Review Committee (DRC)  ............................................................................. 36 
11 APPENDIX 1:  ................................................................................................................... 38 
11.1  PCDAI  ........................................................................................................................ 38 
12 APPENDIX 2:  ................................................................................................................... 41 
12.1  PUCAI:  ....................................................................................................................... 41 
13 APPENDIX 3:  ................................................................................................................... 43 
13.1  CDAI  .......................................................................................................................... 43 
14 APPENDIX 4:  ................................................................................................................... 44 
14.1  MAYO SCORE  .......................................................................................................... 44 
15 APPENDIX 5:  ................................................................................................................... 45 
15.1  SES-CD SCORE ......................................................................................................... 45 
 
  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 8 of 48 1 BACKGROUND AND RATIONALE  
 
1.1 Inflammatory Bowel Disease:  
 The purpose of this protocol is to study  the safety and tolerability of  MSCs for the 
treatment of pediatric and young adult patients with moderate to severe Inflammatory Bowel Disease (IBD), including Crohnâ€™s  disease (CD) and ulcerative colitis (UC), which 
is unresponsive to conventional therapy. CD and UC are chronic inflammatory diseases characterized by relapsing inflammatio n of the gastrointestinal tract. There is no known 
cure for these lifelong conditions. CD affects the full thickness of the bowel wall, and may affect the different areas of the small and large intestine.  Conversely, UC affects only the large intestine.   
 
IBD in children profoundly affects nutrition, growth, education, employment, and social 
well-being.  The prevalence of CD in people < 20 years of age is 43 per 100,000 and for 
UC is 28 per 100,000 in the US.  Overall, the cost associated with IBD care is  greater in 
children than in adults.  This likely reflects the high number of incident cases in children, but also likely reflects the increased severity of IBD in children. [ 5]   Though a much 
lower prevalence is found in other areas of the world, IBD appears to be emerging in areas such as China, South Korea, India, and Iran, correlating with industrialization and westernization.  [6]  Twenty -five to 30% of all patients wit h CD and 20% of those with 
UC are diagnosed before age 20. [ 7]  [8]  
 
Although exact details of the disease pathogenesis are unknown, the generally accepted hypothesis is that IBD occurs as an exaggerated and dysregulated mucosal immune  response to environmental factors, including intestinal microbiota, in a 
genetically susceptible host.  The hallmark of IBD is an infiltration of innate immune cells (neutrophils, macrophages, dendritic cells, and natural killer T cells) and adaptive immu ne cells (B cells and T cells) into the intestinal lamina propria. Innate immune cells 
provide a rapid response to microbes via sensors (i.e. toll -like receptors) which 
recognize microbial and nonmicrobial triggers and initiate inflammatory responses.  In CD, failure of dendritic cells to induce tolerogenic regulatory CD4+ T cells leads to a cascade of intestinal inflammation.  [9] CD is characterized by an imbalance of elevated 
pro-inflammatory effector T cells (Th17 and Th1 cells secreting cytokines interleukin- 17 
and 22, interferon Î³ and TNF Î±) and decreased inflammatory -suppressing regul atory T 
cells. [10, 11] Th2 cytokines secreted by natural killer T cells are implicated in UC. [ 12] 
[10]   
 
1.2 Current Standard IBD Treatment:  
Treatment goals in pediatric IBD include improving quality of life, maximizing growth and 
nutrition, and preventing complications, such as toxic megacolon,  anemia,  intra-
abdominal abscess, intestinal obstruction, intestinal perforation, growth failure and 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 9 of 48 pubertal delays.   In spite of advances in IBD therapeutics, a significant number of 
patients continue to have symptoms while on conventional medications. Moderate to severe IBD is treated with systemic corticosteroids, immunomodulators (6-mercaptopurine f or CD and UC, methotrexate for CD), and biologics (i.e. infliximab, 
adalimumab, certolizumab). These medications are variably effective and have potential for severe complications and side effects.  From the first introduction of corticosteroids, 20% of pa tients do not respond, and 35% of the responders develop steroid 
dependency. [13, 14] 6-mercaptopurine and its parent drug azathioprine possess well -
known immunosuppressive and lymphocytotoxic properties. [ 15] While 50% of patients 
will achieve a clinical response after 4 months of therapy,  only 4 0-65% of patients 
maintain remission, and the onset of these drugs is slow. [16, 17]  Methotrexate is 
effective in about a third of patients with CD, although experience with methotrexate in pediatric IBD literature is scant and retrospective. [ 18] Toxicities, particularly 
teratogenicity in females, limit its use. Methotrexate may also cause nausea, bone marrow suppression,  infections, and liver injury.  
 Biologic therapies are widely used for treating both UC and CD.  Established and 
emerging therapies for IBD are directed toward the destruction or deterrence of activated effector T cells, or blockade of Th1- driving cytokines. Trials with anti -cytokine 
therapy, in particular anti -TNF Î± medications, have been successful for patients with 
refractory disease.  There are 4 anti -TNF monocolonal antibodies currently FDA 
approved for use in adults with IBD: infliximab, a chimeric IgG1 antibody; adalimumab, a fully humanized IgG1 antibody; certolizumab and golimumab, both PEGylated 
humanized Fabâ€™ fragments. [19] However, there are fewer options for pediatric patients, 
as only infliximab is FDA approved for pediatric UC, while both adalimumab and 
infliximab are indicated for treatment of pediatric CD.  Despite these advances, one third of patients do not respond t o these medications, and an additional third subsequently 
lose response or become intolerant. [20, 21]  
 
Safety data from the use of TNF inhibitors highlight concerns regarding risk of 
infections, such as tuberculosis, listeria, pneumocystis, and invasive fungal organisms.  It is known that concomitant use of immunomodulators improves clinical efficacy of infliximab in adults. [22, 23]  However, serious risks are associated with infliximab and 
immunomodulators. In addition to infection, include infusion/injection reactions, hepatitis, and an otherwise extremely rare and almost uniformly fatal hepatosplenic T -
cell lymphoma in pediatric and young adult CD patients receiving the combination of 
infliximab and 6MP or azathioprine. [24, 25]  Thus, a need for new therapies for 
refractory pediatric IBD exists, particularly the need for safely modulating the immune system to reduce or reverse the abnormal inflammatory cascade.  
 
 
 
 1.3 Description of the Study Agent/Intervention 
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 10 of 48 Human Mesenchymal Stromal Cells (MSCs) -  â€œUniversal Stem Cellsâ€   
 
MSCs are undifferentiated, non- hematopoietic , pluripotent cells that give rise to 
mesodermal tissue types, including bone, cartilage, tendon, muscle, and fat. [ 26] MSCs 
provide support for the growth and differentiation of hematopoietic  progenitor cells in 
bone marrow microenvironments and, in animal models, promote engraftment of hematopoietic  cells. [27] These cells may be isolated from most human tissues, usually 
bone marrow, and expanded ex vivo . [28, 29] MSCs do not express the hematopoietic  
markers CD45, CD34, and CD14, or the co- stimulatory molecules B7- 1, B7 -2, CD40, 
CD40 ligand, CD80 and CD 86 and probably therefore do not activate alloreac tive T 
cells. [30-32]. Minimal classification criteria has been defined as positive for CD146, 
CD90, and human leukocyte antigen (HLA) class 1 and negative for hematopoietic  cell 
markers. [33] MSCs constitutively express HLA class I molecules, but do not express 
class II molecules on the cell surface.  In the presence of inflammatory cytokines, i.e. 
IFN Î³ and TNF ð›¼ð›¼, the surface expression of class I is increased and class II expression 
is induc ed. [32] However, mesenchymal tissues, such as bone and cartilage have been 
successfully transplanted without the need for donor -recipient MHC matching, and the 
incidence of acute rejection of these tissues is low.  Thus, the mesodermal origin of 
BMSCs, along with lack of co -stimulatory molecules necessary to activate T cells, 
suggests low i mmunogenicity of these cells.  MSCs isolated from humans and other 
mammalian species do not elicit a proliferative T cell response from allogeneic lymphocytes. [34, 35] 
 
MSCs have been shown to possess immunomodulatory properties, following the initial 
observation that bone marrow -derived MSCs suppressed T cell proliferation. [ 36]  As 
expected, MSCs suppress proliferation of allogeneic T cells in a dose- dependent, non-
HLA-restricted manner. [30, 32, 37] MSCs inhibit the division of stimulated T cells by 
preventing their entry into the S phase of the cell cycle and by mediating irreversible 
B0/G1 phase arrest. [38]  MSCs interact with other immune cells and are capable of 
alteri ng immune cell responses.  MSCs can inhibit the differentiation of monocytes into 
immature dendritic cells. [39] MSCs also impair the ability of DCs to express co-
stimulatory molecules, produce cytokines, and stimulate T cells. [ 40] MSCs can 
decrease the pro- inflammatory potential of dendritic cells by inhibiting their production of 
tumor -necrosis factor (TNF) and IFN -Î³.[41]  MSCs increase production of IL- 10, thereby 
limiting T cell expansion. [ 41]  Suppression of T cell responses is in part mediated by 
incompletely defined soluble factors, and MSCs may also suppress T cell reactivity by inducing T regulatory cells. [ 42] 
 
A critical benefit of MSCs is that they do not seem to induce immunological memory in the recipient even when they are completely HLA mismatched, to the point of avoiding rapid rejection.  [43] Given the goal of healing intestinal mucos a, another possible 
benefit of MSCs is that they have been shown to promote tissue repair and healing after radiation injury. Infused MSCs improve the outcomes of acute renal, neural, and lung injury, perhaps leading to a switch from pro -inflammatory to anti -inflammatory cytokines 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 11 of 48 at the site of injury. [ 44]  Thus, much research has been f ocused on the potential use of 
MSCs for the treatment of chronic wounds, degenerative diseases, autoimmune 
diseases, and graft -versus- host disease. [45-48]  The vast majority of studies of MSCs 
have been performed in adults.  
 
 
1.4 Scientific Rationale and Clinical Justification  
 
1.4.1  Rationale for the study of BMSCs in Pediatric IBD  
 Pediatric IBD is a chronic, life -long condition beginning in childhood, characterized by 
relapsing inflammation of the gastrointestinal tract.  Inflammation is thought to be mediated by T cells, macrophages, and dendritic cells that produced  downstream 
cytokines.  Despite the many therapeutic advances in the treatment of IBD, many patients still suffer with refractory disease.  Children with IBD are typically exposed to multiple medications over years, and many suffer with associated serious side effects.  
 According to 2009 US Census data, inflammator y bowel diseases (IBD) (i.e. Crohn's 
disease  and ulcerative colitis) affect  about 1.2 million Americans. Of these, 62,000 are 
children (38,000 CD and 23,000 UC).  Thus, 5% of all IBD cases in the USA are of 
pediatric age (<20 years). This qualifies drugs to treat pediatric UC and pediatric CD as 
orphan indications.   
(
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfmIndex_Nu
mber=340911 ) Further, while there are options for the treatment of IBD in adults, other 
than corticosteroids , infliximab  (Remi cade)  and adalimumab (Humira)  are FDA-
approved for the treatment of moderate to severe pediatric CD.   Infliximab has orphan 
drug designation to treat pediatric UC .  Certolizumab pegol, methotrexate, 6MP, and 5-
ASA products are NOT FDA approved for use in children with UC or CD.  
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ ) 
 The scientifi c rational e for investigating the use of MSCs in IBD patients is based on 
known properties of inflammatory and immune modulation and enhancement of tissue repair.  This is not a first -in-human study  and there is now a sizable body of evidence 
that this intervent ion is safe when used in people â‰¥ 18 years of age.  However, the 
safety of MSCs has not been yet demonstrated  in children with IBD.  While children 
cannot be treated as â€œsmall adultsâ€, this is  not an intervention that is expected to have 
substantially different impact on children than adults because metabolic differences are not a concern for this intervention.   CD and UC are considered similar enough that 
efficacy in children has been extrapolated from adults  in past trials of drugs used to treat 
IBD.   
 
Therefore, there is an urgent medical need  to evaluate novel therapies such as MSC s in 
pediatric IBD since:  
1). Children with refractory IBD have few well -studied treatment options.  
2). MSC therapy has already been evaluated in adults  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 12 of 48 3). There is not only the potential for benefit when using MSC in IBD but also the high 
likelihood that the allogeneic MSC will not  cause the systemic immune suppression 
seen with other investigational therapies for this disease.  
 The MSCs that we propose using are different because they are passaged fewer times  
(up to 4 passages) . One of the limitations when expanding MSCs is the time, labor, 
necessary space and costs associated with the expansion of these cells.  For example, to generate 500 million MSCs using standard T -175cm2 flasks requires four -five 
passages and as many as 200 flasks by the final passage. One way to circumvent these limitations is to use a functionally -closed, automat ed bioreactor that expands a 
large number of cells in a short period of time, such as the Quantum Cell Expansion system. Besides being a closed system (which limits the chance of contamination), the bioreactor requires only about 20% of the labor that the normal flask -based expansion 
requires and manufactures the cells 1- 2 weeks sooner. In addition, the Quantum can 
produce 200- 400% more cells during the same time period. In Dr. Hanleyâ€™s preliminary 
pre-clinical studies, >500 million MSCs can be expanded aft er only two passages with 
the potential to generate over 1 billion MSCs by passage two, and over 2.5x10
10 MSCs 
by passage three. In these same studies, cells obtained from the Quantum had a similar phenotype to those expanded in flasks. We are one of the f ew centers with a Quantum 
system.  Dr. Hanley is an established expert in the manufacturing of MSCs for phase 1 trials, as well as the Director of the GMP facility at CNHS.  [ 49, 50]     
Our cell therapy product consists of allogeneic mesenchymal stromal cells manufactured from an eligible normal donor .  We have a CNMC IRB -approved protocol  
(Pro00006717)  that provides a mechanism for the use of excess bone marrow obtained 
from healthy donor bone marrow harvests . Up to 100 mL of marrow will be obtained 
from Lonza (Walkersville, MD) under informed consent and transported to Childrenâ€™s National Health System  in a validated process at 2- 8Â°C. The donor will meet the 
eligibility requirements as described in 21 CFR parts 1271 Subpart C. Testing (Table 1) will be performed using FDA -approved, cleared and/or licensed kits by Lonza within 7 
days of collection of the marrow for manufacturing. Manufacturing will commence within 
24 hours of marrow collection. Risk factors will be assessed by taking a clinical history, clinical examination, and by use of a standard questionnaire for blood donors.  
 
 
 
 
This would not be a first -in-human 
study and there is now a sizable body 
of evidence that this intervention is safe when used in people â‰¥ 18 years 
of age.  However, the safety of MSCs has not been yet demonstrated in Table 1:                      Test 
Chagas Disease  
Hepatitis B Surface Antigen  
Hepatitis B Core  
Hepatitis C Core  
HIV 1 and 2  
TAQ Screen MPX (HBV, HCV, HIV -1 group M RNA, 
HIV-1 Group O)  
NAT HCV  
NAT West Nile Virus  
Serological Test for Syphilis  
CMV  
HTLV -1 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 13 of 48 children with IBD.  Safety and dosing m ay not be extrapolated from adult studies, as 
classic pharmacokinetic monitoring to document equivalent exposure- response is not 
feasible with cell therapies.  
 
1.4.2  PLAN OF STUDY:  
 
This is a pilot phase 1 treatment protocol for subjects with moderate to severe CD or UC 
who have failed or are intolerant of one biologic .  Subjects must have had a flexible 
sigmoidoscopy or colonoscopy or MR enterography within 2 months of enrollment, 
demonstrating active inflammatory bowel disease.  Subjects with moderate to sever e 
CD are defined differently in children and adults.  In patients < 17 years  of age, 
moderate to severe CD will be defined as having a  Pediatric Crohn Disease Activity 
Index (PCDAI) score of > 30 (range 0- 100) and subjects with moderate to severe UC 
are defined as a patients with a Pediatric Ulcerative Colitis Activity Index (PUCAI) score 
of >34 (range 0- 85).  In patients â‰¥ 1 8 years of age, moderate to severe CD will be 
defined as a CDAI of â‰¥ 220 (range 0- 600), and moderate to severe UC defined as a 
Mayo score of â‰¥ 6 (range 0- 12).  In our study, at the specification of the FDA IND 
review, a young adult cohort will be enrolled first and monitored for toxicity.  A pediatric 
cohort will only begin to enroll if there are no serious adverse events observed in t he 
young adult cohort. Subjects will be closely monitored both by the study team to detect and evaluate adverse events (AEs), serious adverse events (SAEs), and toxicity requiring discontinuation of the intervention.   
Three young adult patients (ages 17  â‰¤ 22  years) will be enrolled, staggered by at least 
7 days.  A fixed dose will be studied:  1 x 10
6 cells/kg administered intravenously (IV) 
weekly for 4  consecutive weeks.  Infusions are administered over the first 28  days, 
followed by a 45 day monitoring  period.  Our chosen dose (1 x 106 cells/kg weekly for a 
duration of 4  weeks) is within the dosing parameters of previous trials.  In trials of MSCs 
in pediatric GvHD, doses as high as 8 x 106 cells/kg/dose were given up to twice per 
week for four weeks. [ 51] The rate of administration (for patients < 35 kg, total infusion 
over 60 minutes, and for â‰¥ 35 kg, 4 -6 ml/minute via infusion pump) is also consistent 
with prior pediatric administration in patients with GvHD. [ 51]   
In our study, toxicity will be scored as a binary variable indicating occurrence or non-occurrence over a monitoring interval from the start of MSC therapy to 45 days after the last infusion. Based on the planned administration schedule, the total toxicity  monitoring 
period will have duration 28  +45 = 73  days.    If we observe no severe (grade 3 or 
worse) adverse events in the young adult cohort, we will wait a minimum of 45 days before beginning to enroll 3 more patients, ages 12â‰¤ 16 years (pediatric cohort ).  If we 
observe a severe (grade 3 or worse) adverse event occurring at any time from the start of therapy to 45 days following the last MSC administration in the young adult cohort we 
will stop the study. If we observe no SAEs  attributed to MSC administr ation in the young 
adult cohort but an SAE (grade 3 or worse) occurring at any time from the start of 
therapy to 45 days following the last MSC administration in the pediatric cohort, we will 
stop the study. If patients with active disease do not have >grade 2 toxicity attributed to 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 14 of 48 cells and fail to rapidly progress with disease requiring urgent therapy  or surgery , and at 
the discretion of the principal investigator , 4 additional weekly doses  may be 
administered .  Subjects  are eligible to receive up to 4 additional doses of MSCs  at 
weekly  intervals , each of which will consist of the same cell number  (1 x 106 cells/kg ). 
The safety  assessment  period  will be 45 days from the last dose administered. A 
maximum of 6 patients will  be enrolled. Assuming an accrual rate of 3- 4 patients per 
year, it is anticipated that it may require at least 18-  24 months to accrue all 6 patients. 
With the additional 24 months of follow up to evaluate longer -term safety and efficacy 
endpoints, the anticipated trial duration will be about 48 months.   
The primary study endpoint is safety and tolerability of the administration of human 
allogeneic bone marrow -derived MSCs to children and young adults with IBD, 
measured by the frequency of any SAEs, AEs and/or early treatment discontinuations. Secondary endpoints will include: 1) magnitude of change  in clinical indices  CDAI, 
Mayo, PCDAI and PUCAI) relative to baseline, reporting the average decline and 95% confidence limit;  2) changes  in biomarkers  (i.e. C -reactive protein, fecal calprotectin, 
anti-HLA antibodies  and viral specific T -cell activity .) and 3)  where available, magnitude 
of endoscopic improvement, as assessed by change in endoscopic scores (Simple Endoscopic Score Crohnâ€™s Disease [SES -CD] for CD or Endoscopic Sub Score within 
the Mayo Score for UC) relative to baseline, reporting the average dec line and 95% 
confidence intervals [3, 4] . 
We will collect serum, saliva, peripheral blood mononuclear cells, stool, and urine for 
study of known and potential biomarkers of disease response. A potential concern regarding this therapy is the effect upon T c ell-mediated immunity. Thus, we will assess 
peripheral viral -specific T cell activity before and after therapy.    
 The trial has been registered at clinicaltrials.gov (#[STUDY_ID_REMOVED]) . The IND has been 
reviewed and approved at the Center for Biologics Evaluation and Research at the FDA (IND#15902).   
 Safety and dosing may not be extrapolated from other populations , and classic 
pharmacokinetic monitoring is not feasible with cell therapies. A young adult cohort will be enrolled and monitored for toxicity.  A pediatric cohort will only begin to enroll if there are no serious adverse events observed in the young adult cohort. Subjects will be closely monitored both by the study team and an independent DRC to detect and 
evaluate adverse events, serious adverse events, and toxicity requiring discontinuation 
of the intervention.  Participants will be followed closely with weekly follow -up and 
assessment during the treatment protocol, and a subsequent 45 day follow up period 
after last MSC infusion . Laboratory and clinical data will be collected per protocol.  
 
 
1.4.3  Rationale for the Dosage and Treatment Period  
 
Our chosen dose1 x 10
6 cells/kg weekly x 4weeks  is within the dosing parameters of 
previous trials .  In trials of MSCs in pediatric GVHD, doses as high as 8 x 106 
cells/kg /dose  were given up to twice per week for four weeks. [ 51] The rate of 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 15 of 48 administration (for patients < 35 kg, total infusion over 60 minutes, and for children â‰¥ 35 
kg, 4 -6 ml/minute via infusion pump) is also consistent with prior pediatric administration 
in patients with GVHD. [ 51]   
 
2 STUDY OBJECTIVES AND DESIGN  
 
2.1 Study Objectives:  
 
2.1.1  Primary Objective:  
 
The primary objective is to examine the safety and tolerability of infusions of fresh bone 
marrow -derived MSCs in the treatment of children and young adults  with moderate to 
severe IBD .   
 
2.1.2  Secondary objectives:  
 
 
1. Examine  the effects of 4 infusions of MSCs on clinical measures of disease activity in 
patients, using clinical indices, as well as endoscopic  scores (if applicable) , histologic 
scores, and MR enterography  when available.  
 2. Examine inflammat ory and immunologic effects of MSC infusions on peripheral and 
intestinal mucosal biomarkers including, but not limited to serum CRP, fecal calprotectin, anti-HLA antibodies , and viral specific T -cell activity  before and after 
treatment.  
 
2.2 Study Design  
 
This study is a pilot phase 1 treatment protocol for subjects with moderate to severe CD 
or UC who have failed to respond to or are intolerant of a biologic. Patients must have 
had a flexible sigmoidoscopy, colonoscopy  or MR enterography  within 2 months of  
enrollment, demonstrating active inflammatory disease.   
 Two types  of patients will be enrolled:  
 - Moderate to severely active CD subjects (defined in Section 2.4)  
- Moderate to severely active UC subjects (defined in Section 2.4)   
 At the beginning of the trial, a history and physical examination will be obtained, and 
documentation of baseline co- variates
[52]: 
CD:  
o age  
o gender  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 16 of 48 o ethnicity  
o history of abdominal surgery  
o duration of time with diagnosis  
o age at diagnosis  
o disease location  
o  history of failed biologic use  
o history of stricturing/penetrating disease  
o positive family history of IBD  
o history of perianal disease  
o severity and phenotype (Montreal classification for adults, or Paris classification  
for children)  
 
UC:  
o age  
o gender  
o ethnicity  
o age at diagnosis  
o history of failed biologic use  
o duration of time since  diagnosis  
o positive family history of IBD )     
 
During the course of the patientâ€™s  treatment with MSCs, standard of care will be 
administered by the treating physician, at his/her discretion. There are no specific or 
â€œantidotalâ€ therapies.  Thus, any toxicity that arises during a patientâ€™s participation in this treatment will be managed with supportive  measures at the discretion of the treating 
physician.    
 
Three young adult patients (ages 17 â‰¤22 years) will be enrolled, staggered by at least 7 
days  between patients , and each monitored for toxicity
 over a period of 73  days.  A 
fixed dose will be studied:  1 x 106 cells/kg administered intravenously (IV) weekly for 4 
consecutive weeks.  Infusions are administered over the first 28  days, followed by a 45 
day monitoring period.  The primary outcome  is regimen- related toxicity, defined in 
section 5.  Toxicity will be scored as a binary variable indicating occurrence or non-occurrence over a monitoring interval fro m the start of MSC therapy to 45  days after the 
last infusion. Based on the planned administration schedule, the total toxicity monitoring period will have duration 28  +45 = 73 days.    
If we observe no severe (grade 3 or worse) adverse events in the young adult cohort, we will wait a minimum of 45 days before beginning to enroll 3 more patients, ages 
12â‰¤16 years  (pediatric cohort).  If we observe a severe (grade 3 or worse) adverse 
event  occurring at any time from the start of therapy to 45 days following the last MSC 
administration in the young adult cohort we will stop the study. If we observe no severe 
adverse events attributable to MSC administration in the young adult cohort but a 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 17 of 48 severe (grade 3 or worse) adverse event occurring at any time  from the start of therapy 
to 45 days following the last MSC administration in the pediatric cohort we will stop the 
study.  A maximum of 6 patients will be enrolled. Assuming an accrual rate of 3 -4 
patients per year, it is anticipated that it wil l require at least 18 â€“ 24 months  to accrue all 
6 patients. With the additional 24 months of follow up to evaluate efficacy endpoints 
noted in Section 2, the anticipated trial duration will be about 48 months.   
  
2.2.1  Primary Endpoint  
 
Safety and tolerability of the administration of human allogeneic bone marrow -derived 
stromal cells to children and young adults with IBD, measured by the frequency of any SAEs, AEs and/or early treatment discontinuations.  
 
2.2.2  Secondary Endpoints   
 
ï‚§ Magnitude of change in PCDAI , PUCAI , CDAI  to baseline, reporting the average 
decline and 95% confidence limit.  
â€¢ Changes  in laboratory parameters indicating inflammation or immunogenicity (i.e. 
C-reactive protein, fecal calprotectin,  anti-HLA antibodies , and viral specific T -cell 
activity ))  
â€¢ When available, magnitude  of endoscopic improvement, as assessed by change 
in endoscopic scores (Simple Endoscopic Score Crohnâ€™s Disease [SES -CD] for 
CD or Endoscopic Sub Score  within the Mayo Score for UC) relative to bas eline, 
reporting the average decline and 95% confidence intervals.  
 
2.2.3  Exploratory Endpoint  
 
â€¢ Blood, urine, saliva, and stool will be collected  for evaluation of biomarkers  
 
2.3 Study Population  
 
This treatment protocol allows for the treatment of both male and female young adults 
and children between the ages of  12 years and 22  years with a diagnosis of moderate 
to severe CD or UC who have failed or are intolerant of  biologic therapy.  
 Subjects with moderate -to-severe CD are defined as patient with a  PCDAI  score  > 
30 with visually active CD at the time of endoscopy/colonoscopy , or signs of 
inflammation on MR enterography, within 2 months of enrollment.  
 
Subjects with moderate -to-severe active UC are defined as a patient with a  PUCAI  
score >34, and visually active mucosal disease by colonoscopy  or flexible 
sigmoidoscopy  within past 2 months.  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 18 of 48  
2.4 Recruitment Plan  
 
Subjects will be recruited from the IBD Program at Childrenâ€™s National Medical Center , 
and from other sites via provider communication. The trial will be listed at 
clinicaltrials.gov.  
 
2.5 Informed Consent  
 
The informed consent process will be conducted in a private room to respect subject 
privacy. Following the briefing of the research study, the coordinator or designee will provide the subject with ample time to read the consent, and will answer any of their questions regarding the document. No study procedures will occur before the subject gives informed consent. To minimize any possible coercion, supervisors or anyone in a dominant posit ion will not be permitted to consent the subject. The treating physician is 
responsible for ensuring that written informed consent, including written authorization for use and disclosure of PHI and appropriate signatures and dates, is obtained from each patient before any protocol -related procedures, including any pre- treatment procedures, 
are performed.  All patients who are <18 years of age will require a parental or legal guardian signature of informed consent.  In addition, all patients between the ages of 12 
and 17 years will require a signature of assent.  
 Prior to the subjectâ€™s participation in any trial procedures, the investigator or designee 
will ensure that the potential participant understands the research study and their role in the study.  The written informed consent will be signed and dated by the subject and by the person who conducted the informed consent discussion. A signed copy of the consent form will be placed in the subjectâ€™s trial chart and a photocopy will be given to the subject . Informed consent will be obtained in accordance with the Code of Federal 
Regulations (CFR) 21 CFR 50.25, 32 CFR 219, 45 CFR 46 and 15- 2, ICH Harmonized 
Tripartite Guidance for Good Clinical Practice, and the Belmont Report. Also included in the consent process, Health Insurance Portability Accountability Act (HIPAA) authorization will be obtained before any study procedure is undertaken.  
 If subject decides to take part in the research study, their protected health information 
will not be given out except  as allowed by law. Study personnel will work hard to keep 
this information private. The results of the data from the study may be published. However, subject will not be identified by name.  
 Subject s may change their mind and withdraw from the study any time they want.  
 
If they decide to stop taking part in the study or if they are removed from the study, they 
may decide that they no longer allow protected health information that identifies them to be used in this research study. The study staff will respect the subject's decision to 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 19 of 48 decline access to their medical records and biological samples. Subject decision will be 
available in their records.  
 If subject agrees to participate in this research st udy, the research team (PI, co-
investigators, Clinical Research Manager, statistician, Clinical Research Coordinator, Quality Assurance coordinator, and Research Nurse), the research sponsor (when applicable) and the sponsor's representatives, may use  code d study data. The coded 
study data does not include subject name, address, telephone, or social security 
number. Instead, the researcher assigns a code to the data.  The research team or the 
research sponsor may share the coded study data  with others to per form additional 
research, place it into research databases, share it with researchers in the U.S. or other countries, or use it to improve the design of future studies. They may also publish it in scientific journals, or share it with business partners of the sponsor and to file applications with U.S. or foreign government agencies to get approval for new drugs or health care products.  
 The research team would store personal health information collected from the study in a database in a password protected c omputer for future research. The database is 
maintained by Childrenâ€™s National Medical Center in the division of Blood and Marrow Transplantation.  
 
2.6 Eligibility criteria  
 
2.6.1  Subject Inclusion Criteria  
â€¢ For the young adult cohort, patients must be  ages 17 â‰¤22 years  
â€¢ For the pediatric cohort, patients must be ages 12 â‰¤16 years  
â€¢ Patients must have moderate -severely active  CD or UC (defined in section 2.3), and 
documented active disease on flexible sigmoidoscopy , colonoscopy or MR enterography 
within th e preceding 2 months.  
â€¢ Patients who have failed or are intolerant of biologic therapy.  Specifically, the patient will 
have recurrence or persistence of active disease despite current or past treatment with a 
biologic.  At the time of enrollment, study subjects may be currently receiving 5-
aminosalicylates, corticosteroids (â‰¤ 20 mg daily or up to 0.5 mg/kg/day if weight <40 kg), methotrexate, 6MP/azathioprine, or a biologic (either as monotherapy or in combination). 
During the treatment phase, if the treating physician thinks that a medication dose 
should be lowered to avoid side effects, this should be recorded.  
â€¢ Patient or parent/guardian capable of providing informed consent.  
â€¢  
 
2.6.2  Subject Exclusion Criteria  
 
â€¢ Patient <12 years of age or >22 years of age  
â€¢ Pregnant or breastfeeding. Serum pregnancy test must be negative at screening 
for female subjects of childbearing potential. Urine pregnancy test must remain 
negative at each of  4 infusion visits.  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 20 of 48 â€¢ Patients with toxic mega- colon or intestinal perforation  
â€¢ Evidence of autoimmune chronic active hepatitis or sclerosing cholangitis.  
â€¢ Patients with fever > 39Â° C or clinically significant active infection within 1 week 
(i.e. chronic infect ions including Hepatitis B/C or HIV or acute infections, 
including urinary tract infection and respiratory tract infection)  
â€¢ Received an agent not approved by the FDA for marketed use in any indication 
or any small molecule inhibitors (i.e. naltrexone) wit hin 60 days of enrollment.   
â€¢ Subjects who are taking greater than 20 mg (or if body weight <40 kg, 0.5 mg/kg) 
of prednisone daily.  
â€¢ Clinically significant a bnormal biochemical and hematological parameters, 
including:  
o Neutrophil count < 1000 cells/mm3 
o Hemoglobin < 8 g/dl  
o Platelet count â‰¤ 130 cells/mm3 
o Creatinine â‰¥ 1.2 x the upper limit of normal  
o Alanine aminotransferase (ALT) and/or aspartate aminotransferase 
(AST) â‰¥ 2x the upper limit of normal  
o Conjugated bilirubin greater than 1.2 mg/dL  
â€¢ Has active infection with enteric pathogens as evidenced by positive 
microbiological culture of stool or C.difficile toxin PCR.  
â€¢ Had bowel surgery other than perianal procedures (fistulotomy, seton placement, 
abscess drainage) within 3 months of enrollment.  
â€¢ Has uveitis  
â€¢ Has known pulmonary disease, excluding mild intermittent asthma  
 
3 STUDY AGENT  
 
3.1 Preparation Administration, and Dosage  
 
 On the day of each infusion, the following procedures/assessments will be performed:  
 
â€¢ MSC s will be thawed ,  harvested, counted, the viability will be determined, and 
appropriate samples will be sent for other release testing (including sterility). Vital 
signs (heart rate, blood pressure, respiratory rate, and temperature) will be 
measured within 15 minutes prior  to the infusion (time 0) and then every 5 
minutes during the infusion.  If vital signs are normal after three 5- minute checks, 
they will be checked every 15 minutes during the remainder of the infusion,  and 
then at 30 and 60 minutes after the infusion for  1 hour.   
â€¢ Patients will be monitored according to institutional standards for administration of blood products and at a minimum will be monitored according to below:  
o Patients should remain in the clinic for at least one hour  
o Patients should remain on continuous pulse oximetry for at least 30 minutes  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 21 of 48 o Vital signs should be monitored at the end of the infusion then at 30 and 
60 minutes  
â€¢ Per institutional guidelines, pre -medication, consisting of oral acetaminophen 
(10-15 mg/kg/dose, max 650 mg) and diphenhydramine (0.5- 1 mg/kg/dose, max 
50 mg), will be administered at least 30 minutes prior to the infusion.  
â€¢ No other medications should be given during the infusion, unless  determined 
medically necessary by the treating physician.  
â€¢ Supplemental oxygen will be kept by the bedside at all times.  
â€¢ MSCs suspended in Plasmalyte A (multiple electrolyte injection) will be given as an IV infusion using weight -based dosing.  We plan t o infuse 1 -4x10
6 cells per 
mL, not to exceed 240 mL. With a mean weight of 40 kg, the infusion volume would be 40- 120 mL.  
â€¢ Cells  will be infused on Day 0 followed by repeat infusions w eekly over a total of 
4 weeks .  An additional 4 weekly doses may be infused at discretion of physician . 
An attempt will be made to administer repeat infusions from the same initial donor, but administration of MSCs from another donor is permitted if same- donor 
cells are unavailable. Tracking of donor sample identification information will be performed for each sample.  
â€¢ MSCâ€™s will be administered intravenously  via a 18  gauge needle  at a controlled 
rate of 4- 6 ml/minute via infusion pump for patients weighting 35 kg or more. For 
patients under 35 kg in weight, the infusion wil l run in over 60 minutes at a rate 
no greater than 4- 6 ml/minute.  A syringe in combination with syringe pump can 
be used for administration in smaller patients.   
â€¢ During the administration, the infusion must be stopped for any of the following reasons:  
o If the patient has symptoms or signs of respiratory difficulty, including but not limited to tachypnea, cyanosis, complains of shortness of breath, even if the pulse oximet er reading is normal.  If the symptoms resolve within 30 
minutes after standard supportive oxygen therapy, the infusion may be resumed at half the initial rate and the infusion must be completed within 2 hours of starting the infusion.  If the symptoms recur, then the infusion will be stopped and will not be resumed.   
o If SaO2 de creases to â‰¤ 90% over a continuous period of Ëƒ 3 minutes, 
whether or not the patient has symptoms of respiratory distress.  If the SaO2 is â‰¤ 90% in the absence of symptoms or signs, the accuracy of the pulse oximeter reading should be confirmed by using another machine, relocating the sensor, or testing the device on another patient.  
o Infusion may be stopped at the discretion of the treating physician if there 
is another AE that the treating physician believes is related to the infusion, 
or if there is an i ssue with the infusion, or if the patient withdraws consent.  
 
3.2 Assessment of Subject Compliance  
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 22 of 48 All infusions are given under  the direct supervision of the clinical study team , so study 
agent compliance is insured.  
3.3 Concomitant Medications and Procedures  
 
All prescription medications, over -the-counter medications, non- prescription 
medications (including herbal medications) , and concomitant surgical or interventional 
procedures  will be recorded for up to 45 days after last MSC infusion.   At the time of 
enrollment, study subjects may be currently receiving mesalamine, corticosteroids (â‰¤ 20 
mg daily, if body weight < 40 kg, up to 0.5 mg/kg/day), immunomodulators , or biologics. 
If the treating phy sician thinks that a medication dose should be lowered to avoid side 
effects, this should be recorded.    
 
3.4 Prohibited Medications and Procedures  
 
Concomitant non- steroid anti -inflammatory (NSAID) medications will not be permitted 
during study participation.  Other medications used to treat IBD are prohibited other 
than those outlined in the eligibility criteria.  Subjects required rescue IBD therapy before the day assessment will be considered treatment failures.  Medications used to treat medical condition s other than IBD are permitted after review and approval of the 
Principal Investigator. Systemic immunosuppressant for conditions other than IBD is  not 
permitted.  
 
3.5 Study Schedule  
 
Please see below table for detailed schedule of study procedures and assessments  
(table 1).  
 
 
3.6 Table 1: Protocol of Events  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 23 of 48 Visits/Procedures  Screening 
visit Treatment and Safety Monitoring phase  Follow -up Phase  
Visit Day Day -30 to -1 Day 0 
(Dose#1)  Day 7  
(Dose 
#2) Day 14  
(Dose 
#3) Day 21  
(Dose 
#4) Day 28 Day 45  Day 56 aDay 73 Day 180 Day 360 Day 720 
Visit Window  Day -30 to -1 Â± 1 dayb Â± 3 
days  Â± 3 
days   Â± 3 days   Â± 3 days   Â± 3 days   Â± 3 
days  Â±3days Â±28 days  Â±28 days  Â±28 days  
Physical Examination  X     X X X X X X X 
Medical & Surgical 
History  X            
Informed Consent  X            
Active disease on 
sigmoidoscopy, 
colonoscopy, or MR 
enterography  X        
    
Vital Signs  (temp, HR, RR, 
BP) X X X X X X X X X    
SaO2 via pulse oximetry  X X X X X X X X X    
AEs/SAEs   X X X X X X X X   
 
Concomitant Medications  X X X X X X X X X   
 
Eligibility Criteria   X          
 
Collection of serumc, 
saliva,  urine, stool  for 
research  X X X X X X X X X   
 
Urine pregnancy test  
(before each infusion)   X X X X        
MSC infusion   X X X X        
Disease activity 
assesseda X X X X X X X X X X X X 
Routine Labs              
CBC  X X X X X X X X X    
Electrolytes, liver enzymes , urinalysis  X X X X X X X X X    
Quantitative CRP , fecal 
calprotectin  X X X X X X X X X    
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 24 of 48   
 
aDisease activity assessed using: PCDAI, PUCAI, CDAI, Mayo, SES-CD   
bOnly applies to routine labs and pregnancy test  
cWe will draw up to 40 ml of blood at 9 time points for research studies (at baseline before the first infusion, before each subsequent infusion,  and at the 45 day 
safety follow up).
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 25 of 48 3.7 Baseline assessment/screening  
 
During the assessment visit, which will occur during the one month period prior to MSC 
administration, a discussion of the informed consent and signing of the consent will be 
completed prior to the initiation of study procedures .  Medical and surgical history , 
physical  exam ination and labs  will also be performed.  To satisfy enrollment criteria, a 
colonoscopy  or flexible sigmoidoscopy, or MR enterography,  must have been performed 
within the preceding 2 months  for clinic al purposes  to document  active inflammation . If 
possible,  endoscopic assessment  using the SES -CD for CD and the Mayo Score (see 
appendix  4) will be performed .  An upper endoscopy with biopsies may also be 
performed if the physician deems this necessary for clinical assessment. These procedures may be done for clinical purposes at an outside facility, in which case endoscopic scores may not be available.  
 
3.8 Treatme nt Phase (Day 0, 7, 14, 21)  
 
On Days 0, 7, 14 , and 21,  subjects  will arrive at the hospital for infusion of study drug, 
eligibility criteria, laboratory assessments, assessment of AEs /SAEs, collection of 
serum, saliva, urine and stool, and assessment of clinical indices.   
 
Safety Monitoring Phase  (Day  28, 45, 56, 73)  +/- 3 days  
 
During this visit, the patient will return  to Childrenâ€™s National, or be seen by a local 
physician  for a follow -up visit , physical exam, laboratory assessments, AE s/SAEs  
assessment, assessment of clinical indices , bloodwork,  saliva, urine and stool collected 
for fecal calprotectin. Assessment of symptoms and screening for adverse events may 
be done by telephone if necessary.   
 
Follow- up Phase ( Day 180, 360, 720)  +/- 28 days  
Subjects will return to Childrenâ€™s National , or be seen by a local physician, for  a physical 
examination and assessment of clinical indices .  If physical examination is obtained by a 
local physician, reports will be emailed or faxed to the  study  investigator.   Assessment 
of symptoms and screening for adverse events may be done by telephone if necessary.   
 3.9 Study Procedures  
 
Any procedures performed during this study, such as endoscopy, colonoscopy, or MR 
enterography, will be done for clinical purposes.   
3.9.1  Phlebotomy  
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 26 of 48 Research blood will be drawn during screening visit, treatment phase, and safety 
monitoring phase but will not exceed 2 cc/kg or a maximum of 40 ml per blood draw.[53]  
Blood tests run (CBC, CMP, CRP) are considered standard of care.  However, additional tissue specimens (urine, saliva, blood, and stool) may be collected and banked, i f the subject provides consent.   
Any remaining specimens that will be stored for future research will be stored safely and securely in a research specimen storage laboratory at the CETI Laboratory at CNMC . 
 4 POTENTIAL RISKS AND BENEFITS  
 
4.1 Allogeneic BMSC Infusion 
 To date, serious complications or side effects from MSC infusions have not been 
described.  In t he trial by Forbes, et al., of MSCs in the treatment of adults with luminal  
CD, there was one SAE reported:  a subject  diagnosed with sigmoid adenocarcinoma at 
the day 42 endoscopy.   The patient was subsequently found to have had low -grade 
dysplasia on sigmoid mucosal biopsy specimen from the entry endoscopy and there had been a previous recommendation for colectomy because of mucosal atypia within a known proximal rectal stricture. [54] Reported infusion side effects are mild and include 
headache, hives, fever, congestion, and dysguesia (altered taste).  Transfusion reactions and allergic reactions have not been reported in published Phase 1 and II trials.  
  4.2 Phlebotomy  
 Blood draws may cause pain and bruising. Sometimes drawing blood causes people to 
feel lightheaded, and very occasionally causes fainting.  
  
4.3 Possibility of Direct Benefit  
 Subjects may or may not receive any direct benefit from participating in this study.  Subjects may p otentially have a decrease in active IBD symptoms, possible induction of 
remission, and possible improved quality of life.  Study medications and study -related 
routine clinical monitoring tests will be provided free of charge.  Results of any specialized t ests done as part of the study will be made available to interested study 
subjects, their parents, and their healthcare providers.  
  5 DRUG TOXICITY AND/OR ADVERSE REACTIONS  (AES)  
 
Adverse events will be collected as per SOP BMT_SOP003_AE Routine and serious  
adverse events will be collected and reported as per SOP BMT_SOP _004_SAE 
Report.    
 
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 27 of 48 5.1 ADVERSE EVENT   
 
An AE, as defined by the ICH guideline for GCP, is:  
 
Any untoward medical occurrence in a patient or clinical i nvestigation subject 
administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment.   
 
Suspected adverse reaction means any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event. For the purposes of IND safety reporting, "reasonable possibility means there is evidence to suggest a causal relationship between the drug and the adverse event. Suspected adverse reaction implies a lesser degree of certainty about caus ality than adverse reaction, which means 
any adverse event caused by a drug."  
 
An AE is considered to be any adverse change or exacerbation from a baseline 
condition which occurs following the initial administration of an investigational product whether or  not the event is considered to be related to the investigational product. 
Examples of this include but are not limited to the following:  
 â€¢ Adverse changes including new signs and symptoms, intercurrent illness modifying the clinical course, or the worsening of a baseline condition including the increased frequency of an event or an increased intensity of a condition  
â€¢ Concomitant disease wit h onset or increased severity after the start of study 
product administration  
â€¢ A new pattern in a pre- existing condition, occurring after the receipt of 
investigational product that may signal a clinically meaningful change  
â€¢ Clinically significant change s in laboratory values  
 5.2 SERIOUS ADVERSE EVENT  
 As defined by the Code of Federal Regulations (CFR), a serious adverse event (SAE) is any adverse drug experience occurring at any dose that results in any of the following outcomes:  
 
â€¢ Death  
â€¢ Life-threatening adverse event  
â€¢ Inpatient hospitalization or prolongation of existing hospitalization  
â€¢ Persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions  
â€¢ Congenital anomaly/birth defect.  
 
An adverse event or suspected adverse reaction is considered â€œlife- threateningâ€ if, in the 
view of either the investigator or sponsor, its occurrence places the patient or subject at 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 28 of 48 immediate risk of death. It does not include an adverse event or suspected adverse 
reaction that, had it occurred in a more severe form, might have caused death.  
 
Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may  jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.  
 5.3 UNEXPECTED ADVERSE EVENT  
 As defined by 21 CFR 312.32 (a), an unexpected adverse drug experience is:  
 
â€œAn adverse event or suspected adverse reaction is considered "unexpected" if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended.  For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigat or brochure referred only to elevated hepatic enzymes or hepatitis. 
Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected 
(by virtue of greater specificity) if the investigator brochure listed only cerebral vascular accidents. "Unexpected," as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but ar e not specifically mentioned as 
occurring with the particular drug under investigation.â€  
5.4 OTHER ADVERSE EVENT  
 Other adverse events will be identified by the PI during the evaluation of safety data.  
Significant adverse events of particular clinical importance, other than SAEs and those 
AEs leading to discontinuation of the subject from the study, will be classified as other 
adverse events.  For each, a narrative may be written and included in the clinical study report.  
 5.5 RELATIONSHIP TO TREATMENT  
 The PI  or Sub-I must assign a relationship of each AE to the receipt of the 
investigational product.  The investigator will use clinical judgment in conjunction with the assessment of a plausible biologic mechanism, a temporal relationship between the onset of the event in relation to receipt of the investigational product, and identification of possible alternate etiologies including underlying disease, concurrent illness or concomitant medications.  The occurrence of adverse events will be monitored at each 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 29 of 48 visit.  The following guidelines should be used by investigators to assess the 
relationship of an AE to study product administration:    
 
Not related:  No relationship to study treatment.  Applies to those events for which 
evidence exists that there is an alternate  etiology.   For example, events 
that are clearl y related to another medi cal condition (i.e. diabetes) , are 
related to an outside circumstance (i.e. trauma ), or that are not temporally 
related to administration of the treatment.  
 Unlikely:  Likely unrelated to the study treatment.  Likely to be related to factors other than study treatment, but cannot be ruled out with certainty.  The 
need for medical or surgery related to progressive IBD, or known 
symptoms directly related to IBD such as diarrhea,  perianal disease, intra-
abdominal or perianal abscess, intra- abdominal fistula,  rectal bleeding, 
and weight loss are unlikely to be related to the study treatment.  This also 
includes patients with known history of extraintestinal manifestations related to IBD (such as arthralgias, arthritis, uveitis, erythema nodosum, 
pyoderma gangrenosum, or mouth ulcers) who experience such symptoms during the treatment period.   
  
Possible:  An association between the event and the administration of study treatmen t cannot be ruled out.  There is a reasonable temporal 
association, but there may also be an alternative etiology such as the subjectâ€™s clinical status or underlying factors including other therapy. This 
includes known potential risks of IBD and treatments  that the patient is 
receiving, such as infection and lymphoma  
 Probable:  There is a high degree of certainty that a relationship to the investigational product exists.  There is a reasonable temporal association, and the event cannot be explained by known characteristics of the subjectâ€™s clinical state or factors including other therapy.  
 Definite: An association exists between the receipt of investigational product and the event.   An association to other factors has been ruled out.  
 5.6 INFUSION- RELATED ALLERGIC REACTIONS  
 The investigators should ensure that appropriate best clinical practices and treatment are initiated should an event indicating an allergic or hypersensitive reaction occur. Each event will be recorded as an AE or SAE, depending on which criteria are met by 
the event. The start and stop/restart times must be recorded in the CRF.  
 Should an infusion- related allergic reaction occur the infusion will be stopped 
immediately and the subject closely monitored until stable. An infusion- related allergic 
reaction may appear as flushing, sudden rash, or shortness of breath or difficulty breathing.  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 30 of 48  
Definitions and grading will follow the current NCI -CTCAE criteria. Current definition and 
suggested treatment plan for infusion -related allergic reaction:  
 Grade 1: Mild transient reaction  
1. Stop infusion and evaluate for severity. If reaction remains a grade 1 then restart at reduced rate.  
2. Reduce infusion rate by 50%,  
3. Treat subject per good clinical practice (suggest antihistamines, corticosteroids, etc. as medically indicated) and monitor for worsening condition.  
4. If the reaction persists or worsens the infusion will be discontinued.  
 Grade 2:  Readily responds to clinical treatment (e.g., antihistamines, corticosteroids); 
should consider prophylactic treatment for â‰¤24 hours.  
1. Stop infusion for up to 3 hours (product should not be infused after 4  hours).  
2. Administer clinical treatment for allergic reaction as medically indicated.  
3. Resume infusion at 50% of previous rate once reaction has decreased to Grade 
1 in severity. Monitor closely for any worsening.  
4. If the reaction reoccurs, stop infusion. Study treatment is to be discontinued.  
 Grade 3:  Prolonged or severe reaction (e.g., not rapidly responsive to treatment or a 
recurrence of reaction after an initial improvement of a Grade 1 or Grade 2 reaction.  
1. Discontinue infusion immediately. Study treatment is to be discontinued  
2. Administer clinical treatment for allergic reaction as medically indicated.  
3. Report as a SAE  
 Grade 4: Characterized as life- threatening AE; urgent intervention indicated to maintain 
hemostasis.  
1. Discontinue infusion immediately. Study treatment will be discontinued.  
1. Administer clinical treatment for allergic reaction as medically indicated.  
2. Report as a SA E 
  5.7 Severity Assessment  
 All AEs will be assessed for severity by the investigator. Inherent in this assessment is the medical and clinical consideration of all information surrounding the event including any medical intervention required. Each event will be assigned one of the following categories: mild, moderate, severe, or life- threatening. The criteria below may be used 
for any symptom not included in the grading scale. Any grade 4 (life- threatening) AE 
must be reported as an SAE.  
 
Mild                                Grade 1   Does not interfere with routine activities  
                                                                Minimal level of discomfort  
Moderate                      Grade 2          Interferes with routine activities  
                                                                 Moderate level of discomfort  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 31 of 48 Severe                       Grade 3         Unable to perform routine activities  
                                                                Significant level of disc omfort  
Potentially life -threatening Grade 4       Hospitalization or ER visit for potentially  
                                                                life-threatening event  
 
FDA guidelines for toxicity will be followed; however, if a subject is e valuated in an 
emergency room for nonlife threatening illness or symptoms ( i.e., visits emergency 
department on weekend for mild problems because the physicianâ€™s office is closed), the 
information from that visit will be reviewed and severity of the adverse event will be 
assessed according to the subjectâ€™s clinical signs and symptoms.  
 
 The t erm â€œsevereâ€ is often used to describe intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself however,  may be of 
relatively minor medical significance (such as severe headache). This is not the same 
as â€œseriousâ€, which is based on subject/event outcome or action criteria usually associated with events that pose a threat to a subjectâ€™s life or functioning. Seriousness 
(not severity) serves as a guide for defining regulatory reporting obligations.  
 
6 OFF TREATMENT AND OFF STUDY CRITERIA 
 
Off Treatment Criteria for an Individual Subject  
 All patients, regardless of reason for withdrawal, will be asked to continue in the follow -
up phase of the study.  An individual subject may be withdrawn from the study  for any of 
the following criteria : 
 
â€¢ An individual subjectâ€™s decision (the Investigator will attempt to determine the 
reason for the subjectâ€™s decision).  
â€¢ Non-compliance with the study medication and procedures to the extent that it is 
potentially harmful to the subject or to the integrity of the study data.  
â€¢ Worsening of IBD symptoms as defined by a PCDAI greater than 50 or PUCAI greater  than 65.  
â€¢ Subjects requiring rescue treatment for IBD   
â€¢ Any clinical AE, laboratory abnormality, or other medical condition or situation 
such that continued participation in the study would not be in t he best in terest of 
the subject (including changing medication doses due to concern for side 
effects).  
â€¢ A change in the subjectâ€™s baseline condition after enrollment , but prior to start of 
the treatment period so that the subject no longer meets the inclusion/exclusi on 
criteria.  
â€¢ The investigator deems a subject to be no longer fit to participate in the study.  
 Off Study Criteria  for an Individual Subject   
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 32 of 48 â€¢ Completion of study specified procedures.  
â€¢ Refusal of further study follow -up by patient or legal 
guardian  
â€¢ Lost to follow up  
â€¢ Death  
â€¢ Physicianâ€™s discretion  
â€¢ Patient withdrew from study  
â€¢ Other  
 
7 STATISTICAL CONSIDERATIONS  
 
7.1 Statistical Analysis Plan  
 7.1.1. Sample size and follow up . A maximum of 6 patients will be treated in this pilot 
study. It is anticipated that it will require 18- 24 months to accrue 6 patients . With the 
additional 24 months of follow up to evaluate efficacy endpoints noted in Section 2, the anticipated trial duration will be 48 months.  
7.1.4. Safety Monitoring and Stopping Rules . For the purpose of safety monitoring, 
â€œtoxicityâ€ will be defined as a probable or definite regimen related severe (grade 3 or worse) adverse event occurring at any time from the start of therapy to 45 days 
following the last MSC administration.  If we observe 1 severe (grade 3 or worse) adverse event occurring at any time  from the start of therapy to 45 days following the 
last MSC administration in the young adult cohort we will stop the study.  If we observe no attributable severe adverse events in the young adult cohort, but do observe 1 severe (grade 3 or worse) adverse events occurring at any time from the start of therapy to 45 days following the last MSC administration in the pediatric cohort, we w ill stop the 
study.   
7.1.3. Future Trials . If the trial is not stopped early, then the toxicity and efficacy data 
will be used to plan a future trial of MSC cell therapy in pediatric patients with either CD or UC, including (i) blinded placebo- controlled phase II trials optimizing dose or 
adminis tration schedule, or (ii) randomized com parison to standard therapies.  
 
8 RECORDS TO BE KEPT   
 The CETI  Research Office will maintain a password protected, restricted access 
database documenting the dates and doses of therapy as well as clinical chemistries 
and hematologic parameters. The clinical status and occurrence of any adverse events and subsequent interventions are to be kept on all patients.  
o Imaging reports  
o Surgical summaries  
o Autopsy summaries, where a ppropriate  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 33 of 48 o Informed consent documents  
All required clinical evaluation records will be the responsibility of P rincipal Investigator 
who will also be responsible for analysis of the clinical outcome and toxicity.  
The laboratory evaluation of immunological efficacy will be the responsibility of Principal 
Investigator.  
 8.1 Data Handling and Record Keeping 
 
8.1.1  Data Management Responsibilities  
 
The Investigator is responsible for assuring that the data collected are complet e, 
accurate, and recorded in a timely manner.  Source documentation (the point of initial recording of information) should support the data collected in the electronic data system and must be signed and dated by the person recording and/or reviewing the da ta.  All 
data should be reviewed by the Investigator and signed as required with electronic signature.  
 
8.1.2  Data Capture Methods  
 
Data Collection: The OpenClinica database, a 21CFR11.10 compliant database, will be used for data capture. Access to the system will be limited to the study members only. The OpenClinica database will be used to capture data as per the protocol required assessments (see Table 4.2.2).  
 
All required clinical evaluation records will be the responsibility of principal Investigator who will also be responsible for analysis of the clinical outcome and toxicity.  
The laboratory evaluation of immunological efficacy  will be the responsibility of Principal 
Investigator.  
   
8.1.3  Types of Data  
 
Source documents include, but are not limited to, the subjectâ€™s medical records, laboratory reports, ECG tracings, biopsy reports, clinic notes, pharmacy records, and any other similar reports or records of procedures performed during the subjectâ€™s partici pation in the study.  
 
8.1.4  Source Documents and Access to Source Data/Documents  
 
Source documents include all recordings of observations or notations of clinical activities, and all reports and records necessary for the evaluation and reconstruction of the cli nical trial.  Data will be collected directly from subjects during study visits and 
telephone calls, or will be abstracted from the subjectsâ€™ medical records.  The subjectâ€™s medical record must record his/her participation in the clinical trial and study t reatment 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 34 of 48 (with doses and frequency) or other medical interventions or treatments administered, 
as well as any AEs experienced during the trial.  
 
8.1.5  Record Retention  
 
The investigator is responsible for retaining all essential documents listed in the ICH GCP Guideline.  All essential documentation for all study subjects will be maintained by 
the investigators in a secure storage facility for a minimum of 3 years.  The FDA requires study records to be retained for up to 2 years after marketing approval or disapproval (21 CFR 312.62), or until at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational agent for a specific indication.  These records will also be maintained in compliance with IRB, state  and 
federal medical retention requirements, whichever is the longest.  All stored records will be kept confidential to the extent required by federal, state, and local law.  Destruction of research records will not proceed without permission of the IRB.  
 The FDA requires that the Investigator must retain study files for a period of at least 5 years after study completion or 2 years following the date that a marketing application is approved for the indication in which the study agent is being investigated  (whichever is 
later).  
 9 REPORTING REQUIREMENTS   
 
â€¢ Discuss all patients with CNMC Research Nurse  
â€¢ Enter/Register all patients after calling Principal Investigator. The following forms  
should be completed:  
 
ï¯ Eligibility checklist  
ï¯ On study form  
ï¯ Drug Toxicity and/or Adverse Reactions  
ï¯ Adverse events will be collected as per SOPs (BMT_SOP003).  
ï¯ Serious adverse events will be collected and reported as per SOP (BMT _SOP004).   
 
9.1 Adverse Event Reporting 
 Reporting of patient serious adverse events (SAEs) will be consistent with standard BMT SOP (BMT _SOP004_SAEReport).  Unexpected, grades 4- 5AEs must be reported 
within 24 hours of knowledge of the event.  Unexpected, grade 3 AEs must be reported within thr ee business days of knowledge of the event . All other unanticipated problems 
will be reported to the IRB within seven (7) business days of knowledge of the problem. The Data Review Committee (DRC) Board will receive summary reports of all adverse experienc es on at least an annual basis.  
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 35 of 48 9.2 Reporting to the IRB  
 
Following AEs should be considered as unanticipated problems that must be reported to 
the IRB  within seven business days of the knowledge of the AE(s) : 
Single occurrence of a serious, unexpected, and u ncommon event that is strongly 
associated with investigational products exposure 
â€¢ A single or small number of a serious, unexpected event that is not commonly 
associated with investigational products exposure but is uncommon in the study population  
 â€¢ Multiple occurrences of an AE that, based on aggregate analysis, is determined 
to be an unanticipated problem. There should be a determination that the series of AEs represents a signal that the AEs were not just isolated occurrences and involve risk to human subjects  
 â€¢ An AE that is described in the investigatorâ€™s brochure, protocol, or informed consent documents, but occurs at a specificity or severity that is inconsistent with prior observations  
 â€¢ A serious AE that is described in the investigatorâ€™s brochure, protocol, or informed consent documents, but for which there is a clinically significant increase in the expected rate of occurrence  
 
â€¢ Any other AE or safety finding, including those based on animal or epidemiologic data that woul d cause the sponsor to modify the investigatorâ€™s brochure, protocol, 
or informed consent documents, or would prompt other action by the IRB to ensure the protection of human subjects  
 9.3  Pregnancy Reporting 
 Each pregnancy must be reported immediately (within 72 hours  of identification) by 
reportable event submission system  to the CNMC IRB. Subjects who become pregnant 
after Day 0 will be followed to term, and the following information will be gathered for outcome, date of delivery, health status of the mother and child including the childâ€™s gender, height and weight.  Compl ications and or abnormalities should be reported 
including any premature terminations. A pregnancy is reported as an AE or SAE only when there is suspicion that the treatment may have interfered with the effectiveness of contraception or there was a serious complication in the pregnancy including a spontaneous abortion or an elective termination for medical rationale.  
 
9.4 IND Annual Report to the FDA  
 
The PI will be responsible for the preparation of a detailed annual synopsis of clinical activity, including adverse events, for submission to the sponsor.  Each annual report 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 36 of 48 will summarize IND activity for 1 year beginning approximately 3 months before the IND 
FDA anniversary date.  The sponsorâ€™s representative will notify the PI of the due date with sufficient time for the PI to assemble the required information.   
 9.5  Final Report  
 A report will be submitted to the FDA in accordance with ICH E3 Guideline â€œStructure and Content of Clinical Study Reportsâ€.  A final report will also be submitted to the IRB at 
the tim e of study closure.  
 9.6 Reporting to the FDA  
 
Serious adverse events (SAEs) that are unlisted/  unexpected, and at least possibly 
associated to the drug for this study should be reported promptly to the Food and Drug 
Administration (FDA).  Fatal or life threatening SAEs that meet the criteria for reporting to the FDA must be reported to the FDA within 7 calendar days after awareness of the event by submitting FDA form 3500/MedWatch form.  All other SAEs that meet the criteria for reporting to the FDA must  be reported to the FDA within 15 calendar days 
after awareness of the event.  A clear description of the suspected reaction should be provided along with an assessment as to whether the event is drug or disease related.  
  
10 CLINICAL TRIAL OVERSIGHT AND MONI TORING  
  
This protocol will be conducted in accordance with the CNMC BMT Monitoring Plan.  
This protocol will be monitored in accordance with federal regulations and FDA 
guidance documents.  
  The conduct of this clinical trial will be evaluated in accordance with the CNMC BMT Quality Assurance Policy and Procedure Plan (SOP: BMT_SOP010_QA).  
 10.1 Safety monitoring  
 Safety monitoring will be conducted throughout the study; therefore safety concerns will be identified by continuous review of t he data by the PI, clinic staff, and Data Review 
Committee (DRC).   10.2 Data Review Committee (DRC)    
 
The Data Review Committee (DRC) is primarily being established to monitor serious adverse events which may occur during the trial, complete an annual review  of the 
safety data, and to make any recommendations as appropriate. The DRC is required to review all unanticipated problems involving risk to subjects or others, SAEs, and all subject deaths associated with the protocol and provide an unbiased written re port of 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 37 of 48 the event.  The DRC should indicate concurrence or non- concurrence with the details of 
the report provided by the investigator.  Reports for events determined by either the 
investigator or DRC to be related or unrelated to participation and reports  of events 
resulting in death should be promptly forwarded to the IRBs.  
  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 38 of 48 11 APPENDIX  1: 
11.1 PCDAI  
 
History (Recall, 1 week)  
Abdominal Pain     
0=None  5= Mild: Brief, does not interfere with activities  10= Moderate/Severe: Daily, longer lasting, 
affects activities, nocturnal   
Patie  I t Functioning, General Well -
Being    
 mitation of activities, well  5=Occasional difficulty in maintaining age-
appropriate activities, below par  10= Frequent limitation of activity, very poor   
  As (per day)     
  liquid stools, no blood  5= Up to 2 semi -formed with small blood, or 2-
5 liquid  10=Gross bleeding, â‰¥ 6 liquid, or nocturnal 
diarrhea   
    
Laboratory  
HCT  
<10 years (male and female)     11-14 years (Male)  
0= > 3 4% 2.5 = 29-33%   5 = <29%    0 = > 3 5% 2.5 = 30- 34%   5 = < 30%   
 
11-19 years (female)      15-19 years (Male)  
0 = â‰¥ 34%  2.5 = 29- 33%  5 = < 29%   0 = â‰¥ 37%  2.5 = 32- 36%   5 = < 32%  
 
ESR 
0 = < 20 mm/hr    2.5 = 20- 50 mm/hr   5 = > 50 mm/hr  
 
Albumin  
0 = â‰¥ 3.5 g/dL    5 = 3.1- 3.4 g/dL   10 = â‰¤ 3.0 g/dL  
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 39 of 48  
Examination  
Weight  
0 = Weight gain or voluntary weight  5 = Involuntary weight stable,   10 = Weight    
stable/loss     weight loss 1% -9%    loss â‰¥ 10%  
 
Height at Diagnosis  
0  = Ë‚ 1 channel decrease  5 = â‰¥ 1, < 2 channel decrease    10 = > 2   channel decrease  
 Height at Follow -Up 
0 = Height velocity â‰¥ - 1 SD  5 = Height velocity < - 1 SD, > 2 SD   10 = height velocity â‰¤ 2 SD  
Abdomen  
0 = No tenderness, no mass  5 = Tenderness or mass without tenderness  10 = tender ness, involuntary  
       guarding, definite mass  
Perirectal Disease  
0 = None, asymptomatic tags  5 = 1 -2 indolent fistula, scant drainage,  10 = Active fistula, drainage,  
 No tenderness         tenderness, or abscess  
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 40 of 48 Extra -intestinal Manifestations  
Fever â‰¥ 38.5 for more than 3 days in the past week, definite arthritis, uveitis, E. nodosum, P.gangrenosum  
0 = None  5= 1     10= â‰¥ 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 41 of 48 12 APPENDIX 2: 
12.1 PUCAI:  
 
Item                                                             
                                  Points  
1. Abdominal Pain   
No pain  0 
Pain can be ignored  5 
Pain cannot be ignored  10 
  
2. Rectal Bleeding   
None  0 
Small amount only, in 
<50% of stools  10 
Small amount with most 
stools  20 
Large amount (>50% of 
stool content)  30 
  
3. Stool consistency of 
most stools   
Formed  0 
Partially formed  5 
Completely unformed  10 
  
4. Number of stools per 
24 hours   
0 to 2  0 
3 to 5  5 
6 to 8  10 
>8 15 
  
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 42 of 48 5. Nocturnal stools (any 
episode causing 
wakening)   
No 0 
Yes 10 
 
6. Activity Level   
No limitation of activity  0 
Occasional limitation of 
activity  5 
Severe restricted activity  10 
 
   
 
 
     
 
  
 
    
 
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 43 of 48 13 APPENDIX 3 :   
13.1 CDAI  
 
 
      
 
   
 
 
   Clinical or laboratory variable  Weighting factor  
Number of liquid or soft stools each day for seven days  x 2 
Abdominal pain (graded from 0 -3 on severity) each day for seven days  x 5 
General well being, subjectively assessed from 0 (well) to 4 (terrible) each day for seven days  x 7 
Presence of complications  x 20 
Taking Lomotil or opiates for diarrhea  x 30 
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite)  x 10 
Hematocrit of <0.47 in men and <0.42 in women  x 6 
Percentage deviation from standard weight  x 10 
  
One point each is added for each set of complications:   
â—arthralgias or frank arthritis   
â—inflammation of the iris or uveitis   
â—presence of erythema nodosum, pyoderma gangrenosum, or apthous ulcers   
â—anal fissures, fistulae, or abscesses   
â—other fistulae   
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 44 of 48 14 APPENDIX 4:    
14.1 MAYO SCORE  
Endoscopic findings  Normal, inactive disease  0 
  Mild disease, erythema, decreased vascular pattern, mild friability  1 
  Moderate disease, marked erythema, absent  vascular pattern, erosions, friability  2 
  Severe disease, spontaneous bleeding  3 
      
Stool frequency  Normal for the patient  0 
  1-2 more than normal  1 
  3-4 more than normal  2 
  5 or more stools than normal  3 
      
Rectal bleeding  No blood seen  0 
  Streaks of blood with stool less than half the time  1 
  Obvious blood with stool most of the time  2 
  Blood alone passed  3 
      
Physician's Global 
Assessment  Normal  0 
  Mild disease  1 
  Moderate disease  2 
  Severe disease  3 
 
 
 
  
 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 45 of 48  
  
15 APPENDIX 5:  
15.1 SES-CD SCORE  
 
   
Score per Segment  
Variable  0 1 2 3 
Size of ulcers  None  Apthous ulcers (0.1 -0.5 cm)  Large ulcers (0.5 -2.0 
cm) Very large ulcers (> 
2 cm)  
Ulcerated 
surface  None  <10%  10%-30% > 30%  
Affected surface  Unaffected 
segment  < 50%  50%-75% >75%  
Presence of 
narrowing  None  Single, can be passed  Multiple, can be 
passed  Cannot be passed  
                
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 46 of 48  
References:  
   
1. Turner, D., et al., Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.  
Gastroenterology, 2007. 133 (2): p. 423- 32. 
2. Hyams, J.S., et al., Development and validation of a pediatric Crohn's disease activity  index.  J Pediatr Gastroenterol Nutr, 1991. 12(4): p. 
439-47. 
3. Daperno, M., et al., Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES -CD. 
Gastrointest Endosc, 2004. 60(4): p. 505 -12. 
4. Schroeder, K.W. , W.J. Tremaine, and D.M. Ilstrup, Coated oral 5 -aminosalicylic acid therapy for mildly to moderately active ulcerative 
colitis. A randomized study.  N Engl J Med, 1987. 317(26): p. 1625 -9. 
5. Kappelman, M.D., et al., Direct health care costs of Crohn's dis ease and ulcerative colitis in US children and adults.  Gastroenterology, 
2008. 135(6): p. 1907 -13. 
6. Ng, S.C., et al., Geographical variability and environmental risk factors in inflammatory bowel disease.  Gut, 2013. 62 (4): p. 630 -49. 
7. Baldassano, R.N. and D.A. Piccoli, Inflammatory bowel disease in pediatric and adolescent patients.  Gastroenterol Clin North Am, 1999. 
28(2): p. 445 -58. 
8. Kappelman, M.D., et al., The prevalence and geographic distribution of Crohn's disease and ulcerativ e colitis in the United States.  Clin 
Gastroenterol Hepatol, 2007. 5 (12): p. 1424 -9. 
9. Iliev, I.D., et al., Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells.  Gut, 2009. 58(11): p. 1481- 9. 
10. Kobayashi, T., et al., IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease.  Gut, 2008. 57(12): p. 
1682- 9. 
11. Himoto, T., et al., Cytomegalovirus -associated acute gastric mucosal lesion in an immunocompetent host.  Intern Med, 2009. 48(17): p. 
1521- 4. 
12. Fujino, S., et al., Increased expression of interleukin 17 in inflammatory bowel disease.  Gut, 2003. 52(1): p. 65- 70. 
13. Munkholm, P., et al., Frequency of glucocorticoid resistance and dependency in Crohn's disease . Gut, 1994. 35(3): p. 360 -2. 
14. Faubion, W.A., Jr., et al., The natural history of corticosteroid therapy for inflammatory bowel disease: a population- based study.  
Gastroenterology, 2001. 121(2): p. 255- 60. 
15. Podolsky, D.K., Inflammatory bowel disease.  N Engl J Med, 2002. 347(6): p. 417- 29. 
16. Sandborn, W.J., Evidence -based treatment algorithm for mild to moderate Crohn's disease.  Am J Gastroenterol, 2003. 98(12 Suppl): p. 
S1-5. 
17. Markowitz, J., et al., Corticosteroid therapy in the age of infliximab: acute and 1 -year outcomes in newly diagnosed children with Crohn's 
disease.  Clin Gastroenterol Hepatol, 2006. 4 (9): p. 1124- 9. 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 47 of 48 18. Feagan, B.G., et al., A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American 
Crohn's Study Group Investigators.  N Engl J Med, 2000. 342 (22): p. 1627- 32. 
19. Tracey, D., et al., Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.  Pharmacol Ther, 2008. 117(2): p. 244-
79. 
20. Cottone, M. and V. Cris cuoli, Infliximab to treat Crohn's disease: an update.  Clin Exp Gastroenterol, 2011. 4: p. 227- 38. 
21. Rutgeerts, P., et al., Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med, 2005. 353(23): p. 2462- 76. 
22. Vermeire, S. , et al., Demographic and clinical parameters influencing the short -term outcome of anti -tumor necrosis factor (infliximab) 
treatment in Crohn's disease.  Am J Gastroenterol, 2002. 97 (9): p. 2357 -63. 
23. Parsi, M.A., et al., Predictors of response to inflix imab in patients with Crohn's disease.  Gastroenterology, 2002. 123 (3): p. 707 -13. 
24. Lichtenstein, G.R., et al., Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.  Clin 
Gastroenterol Hepatol, 2006. 4 (5): p.  621-30. 
25. Kotlyar, D.S., et al., A systematic review of factors that contribute to hepatosplenic T -cell lymphoma in patients with inflammatory bowel 
disease.  Clin Gastroenterol Hepatol, 2011. 9 (1): p. 36- 41 e1.  
26. Toma, C., et al., Human mesenchymal st em cells differentiate to a cardiomyocyte phenotype in the adult murine heart.  Circulation, 2002. 
105(1): p. 93 -8. 
27. Noort, W.A., et al., Mesenchymal stem cells promote engraftment of human umbilical cord blood- derived CD34(+) cells in NOD/SCID 
mice.  Exp Hematol, 2002. 30(8): p. 870- 8. 
28. Friedenstein, A.J., et al., Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.  
Transplantation, 1968. 6 (2): p. 230- 47. 
29. Pittenger, M.F., et al., Multilineage potential o f adult human mesenchymal stem cells.  Science, 1999. 284(5411): p. 143- 7. 
30. Di Nicola, M., et al., Human bone marrow stromal cells suppress T -lymphocyte proliferation induced by cellular or nonspecific mitogenic 
stimuli.  Blood, 2002. 99 (10): p. 3838 -43. 
31. Majumdar, M.K., et al., Characterization and functionality of cell surface molecules on human mesenchymal stem cells.  J Biomed Sci, 
2003. 10(2): p. 228- 41. 
32. Tse, W.T., et al., Suppression of allogeneic T -cell proliferation by human marrow stromal ce lls: implications in transplantation.  
Transplantation, 2003. 75 (3): p. 389- 97. 
33. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy 
position statement.  Cytotherapy, 2006. 8(4): p. 315 -7. 
34. Mahmud, N., et al., Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched 
mesenchymal stem cell engraftment in a nonhuman primate model.  Exp Hematol, 2004. 32 (5): p. 494 -501.  
35. Grinnemo, K.H., et al., Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium.  J 
Thorac Cardiovasc Surg, 2004. 127 (5): p. 1293 -300.  
36. Bartholomew, A., et al., Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.  Exp 
Hematol, 2002. 30(1): p. 42 -8. 
BMSCs  
                  
                 Version: 3.1, date 01/22/2018  
Page 48 of 48 37. Le Blanc, K., et al., Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic res ponses independently of 
the major histocompatibility complex.  Scand J Immunol, 2003. 57 (1): p. 11 -20. 
38. Glennie, S., et al., Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells.  Blood, 2005. 105(7): p. 2821- 7. 
39. Nauta,  A.J., et al., Mesenchymal stem cells inhibit generation and function of both CD34+ -derived and monocyte -derived dendritic cells.  J 
Immunol, 2006. 177 (4): p. 2080- 7. 
40. Ramasamy, R., et al., Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.  
Transplantation, 2007. 83(1): p. 71- 6. 
41. Aggarwal, S. and M.F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses.  Blood, 2005. 105(4): p. 
1815- 22. 
42. Siegel, G., R. Scha fer, and F. Dazzi, The immunosuppressive properties of mesenchymal stem cells.  Transplantation, 2009. 87(9 Suppl): p. 
S45-9. 
43. Le Blanc, K. and O. Ringden, Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell 
transplant ation.  Biol Blood Marrow Transplant, 2005. 11(5): p. 321 -34. 
44. Semont, A., et al., Mesenchymal stem cells increase self -renewal of small intestinal epithelium and accelerate structural recovery after 
radiation injury.  Adv Exp Med Biol, 2006. 585: p. 19- 30. 
45. Le Blanc, K., et al., Mesenchymal stem cells inhibit the expression of CD25 (interleukin- 2 receptor) and CD38 on phytohaemagglutinin-
activated lymphocytes.  Scand J Immunol, 2004. 60(3): p. 307- 15. 
46. Keating, A., Mesenchymal stromal cells.  Curr Opin Hematol, 2006. 13 (6): p. 419- 25. 
47. Caplan, A.I., Adult mesenchymal stem cells for tissue engineering versus regenerative medicine.  J Cell Physiol, 2007. 213(2): p. 341 -7. 
48. Battiwalla, M. and P. Hematti, Mesenchymal stem cells in hematopoietic stem cell transplantation.  Cytotherapy, 2009. 11(5): p. 503- 15. 
49. Hanley, P.J., et al., Manufacturing mesenchymal stromal cells for phase I clinical trials.  Cytotherapy, 2013. 15(4): p. 416 -22. 
50. Hanley, P.J., et al., Efficient manufacturing of therapeutic m esenchymal stromal cells with the use of the Quantum Cell Expansion System.  
Cytotherapy, 2014.  
51. Prasad, V.K., et al., Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with 
severe refractory acute graft -versus -host disease in a compassionate use study.  Biol Blood Marrow Transplant, 2011. 17(4): p. 534 -41. 
52. Levine, A., et al., Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.  Inflamm  
Bowel Dis, 2011. 17 (6): p. 1314- 21. 
53. Howie, S.R., Blood sample volumes in child health research: review of safe limits.  Bull World Health Organ, 2011. 89 (1): p. 46 -53. 
54. Forbes, G.M., et al., A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells fo r Luminal Crohn's Disease Refractory to Biologic Therapy.  
Clin Gastroenterol Hepatol, 2013.  
 